ASX:MYXPharmaceuticals
Mayne Pharma Group H1 2026 Loss Narrowing Tests Bearish Narratives On Profitability Path
Mayne Pharma Group (ASX:MYX) has released its H1 2026 numbers, posting revenue of A$212.1 million with a basic EPS loss of A$0.15, while trailing 12 month figures show revenue of A$407.1 million and a basic EPS loss of A$1.04. Over recent halves the company has seen revenue sit in the A$195 million to A$213 million range with basic EPS losses between A$0.25 and A$0.89, setting the scene for investors to weigh steady top line scale against ongoing pressure on margins and the path to cleaner...